k 201

JTV-519 is a Ca2+-dependent blocker and prevents abnormal Ca(2+) leak from the sarcoplasmic reticulum in the ischemic heart and skeletal muscle (SkM) by stabilizing the ryanodine receptors.

JTV-519 free base (K201 free base), known for its antiarrhythmic and cardioprotective properties, acts as a Ca2+-dependent blocker of sarcoplasmic reticulum Ca2+-stimulated ATPase (SERCA) and as a partial agonist of ryanodine receptors in striated muscle.

JTV-519 hemifumarate,Antiarrhythmic and cardioprotective properties. is a Ca2+-dependent blocker of sarcoplasmic reticulum Ca2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle.

ARUK2010489 (Compound 23) is a potent, selective, and brain-penetrant NUAK1 inhibitor with a pIC50 of 8.7, also exhibiting partial inhibitory activity against CDK2, CDK4, and CDK6 at micromolar concentrations, and it is applied in neurological disease research, including mechanistic studies related to Alzheimer’s disease.

ARUK2010694 (Compound 20) is a potent and selective inhibitor of NUAK1, with a pIC50 value of 8.7. It also inhibits the activity of CDK2, CDK4, and CDK6, with inhibition rates of 13%, 63%, and 32% respectively at a concentration of 1 μM. ARUK2010694 is applicable in research on neurological disorders, including Alzheimer's disease (AD).

Tirasemtiv (CK-2017357)(CK 2017357) is a small-molecule fast-skeletal-troponin activator, with a potential treatment for muscle weakness and neuromuscular dysfunction.

GSK2018682 is a novel sphingosine-1-phosphate receptor 1 (s1p1) and 5 (s1p5) agonist.

Dibenzosuberenol is a reactant involved in oxidation with tert-butylhydroperoxide in water for synthesis of carboxylic acids and ketones; Synthesis of tachykinin neurokinin-1 receptor antagonists; Pauson-Khand reaction mechanism studies; Mapping the active site of aziridination catalysts.

GSK2018682 is an agonist of sphingosine-1-phosphate receptor (s1p1) and (s1p5) agonist(pEC50s of 7.7 and 7.2,respectively).

VK-2019 is a selective inhibitor of Epstein–Barr virus nuclear antigen 1 (EBNA1) that was developed to specifically block EBNA1 DNA-binding activity, and is currently in phase 1 development for the treatment of EBV-associated carcinomas, supporting research into viral episome maintenance, oncogenic persistence, and targeted antiviral cancer therapies.

Agitoxin-2 TFA, a potent inhibitor of K+ channels, exhibits IC50 values of 201 pM and 144 pM for mK V 1.3 and mK V 1.1, respectively [1] [2].